Navigation Links
Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections
Date:6/30/2009

SAN DIEGO, June 30 /PRNewswire/ -- Calixa Therapeutics Inc. today announced the initiation of a Phase 2 clinical trial of CXA-101 in patients with complicated urinary tract infections. CXA-101 is a new broad-spectrum, parenteral cephalosporin antibiotic with excellent in vitro and in vivo activity against Pseudomonas aeruginosa, including drug resistant isolates. Calixa is investigating CXA-101 as a potential treatment for serious bacterial infections in hospitalized patients.

The multi-center, randomized study is anticipated to enroll approximately 120 patients and will compare the efficacy and safety of CXA-101 with the current standard of therapy. The primary efficacy endpoint for this study is microbiological outcome at the test-of-cure visit between six to nine days after the end of therapy.

"The preclinical and Phase 1 results to date are very promising and indicate that CXA-101 is well tolerated and has broad-spectrum antibacterial coverage, including potent activity against increasingly resistant gram-negative pathogens such as Pseudomonas aeruginosa," said Dr. Ian Friedland, chief medical officer of Calixa. "We are going to present comprehensive preclinical and Phase 1 data at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy in September and other medical conferences. This Phase 2 study will generate important information on the safety and effectiveness of CXA-101 in complicated urinary tract infections, which are usually caused by gram-negative pathogens".

Eckard Weber, president and chief executive officer of Calixa and partner at the venture capital firm Domain Associates, LLC said, "With the continually increasing incidence of serious and life-threatening infections caused by resistant gram-negative bacteria and the paucity of new drugs in the pipeline to counter such
'/>"/>

SOURCE Calixa Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
2. Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
3. Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
4. Horizon Therapeutics HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain
5. InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting
6. Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support
7. Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting
8. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
9. FDA Accepts Arno Therapeutics IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
10. Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
11. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013  Intercept Pharmaceuticals, Inc. (Nasdaq: ... on the development and commercialization of novel bile acid ... biliary cirrhosis, today announced that Mark Pruzanski ... present at the Deutsche Bank Securities 38th Annual Health ... Wednesday, May 29, 2013 at 4:10 p.m. ET. ...
(Date:5/23/2013)... , May 23, 2013  Omeros Corporation ... its Investigational New Drug Application (IND) to evaluate ... the U.S. Food and Drug Administration (FDA). OMS824 ... in areas of the brain linked to a ... Huntington,s disease and schizophrenia. OMS824 has shown promising ...
(Date:5/23/2013)... 23, 2013  MedVantx, Inc., the company that has ... announced today the Company has completed a major expansion ... pharmaceutical products and the upgrade of its systems to ... in its specialty home delivery pharmacy in ... pharmaceutical manufacturers, physicians, health systems and payors novel distribution ...
Breaking Medicine Technology:Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 2MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 3
... N.D., Dec. 16, 2011  Crystal3 Labs, Inc., a cGMP contract ... today that it has been acquired by an individual ... of the transaction were not disclosed. The company also ... Founded in 2007, Global Pharma Analytics provides ...
... ( Medical Device and Diagnostic Industry , UBM ... latest news , information, and in-depth analysis, announced a series of ... of medical device design.  "We,re taking a close ... industry," stated Brian Buntz, Editor for MD+DI. "To some, the focus ...
Cached Medicine Technology:Crystal3 Labs Acquired by Individual Investor, Vithalbhai Dhaduk, M.D. 2MD+DI, the Global MedTech Industry Authority, Highlights the Human Element in Medical Device Design: Designing the Devices Surgeons Want and Pushing the Boundaries of Innovation 2MD+DI, the Global MedTech Industry Authority, Highlights the Human Element in Medical Device Design: Designing the Devices Surgeons Want and Pushing the Boundaries of Innovation 3
(Date:5/23/2013)... 2013 The sodium theory ... and B. Katz in the early 1950s, after their ... of sodium and potassium ions in nerve functions ... acquisition techniques have known amazing developments. In The Sodium ... give an account of the latest developments in the ...
(Date:5/23/2013)... 2013 Orange County film studio and visual ... light leaks for Apple's Final Cut Pro X ... you no longer have to worry about matching up the ... shot," Said Christina Austin, CEO of Pixel Film Studios, "You ... natural look." , ProLeak from Pixel Film Studios allows users ...
(Date:5/23/2013)... Dr. Damon Huffman of Huffman Family Dentistry is ... a revolutionary new treatment method with the Laser Assisted New ... suffer from periodontal disease, and many of them do not ... is hoping that LANAP will encourage many of those people ... , Periodontal disease can cause gums to recede and even ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Funeral Financials ... Memorial Day to the EOD Memorial Foundation ... be the greatest victims from the war. , ... originated in 1941 before the U.S. was even at ... Forces are identified with the Explosive Ordnance Disposal Badge. ...
(Date:5/23/2013)... Lake City, UT (PRWEB) May 23, 2013 ... 3.0 , a comprehensive radiology learning environment for ... with prebuilt lessons and assessments, transforms the learning ... comprehensive radiology curriculum. , “Until RADPrimer ... is second to none,” comments Dr. B.J. Manaster, ...
Breaking Medicine News(10 mins):Health News:Yves Pichon’s New Book Presents Latest Neurophysiological Discoveries 2Health News:Yves Pichon’s New Book Presents Latest Neurophysiological Discoveries 3Health News:Pixel Film Studios Releases ProLeak Light Leaks for Final Cut Pro X Today 2Health News:Humble, TX Dentist, Dr. Damon Huffman Now Offers Laser Periodontal Disease Treatment to Gum Disease Patients 2Health News:Funeral Financials Asks Americans to Donate their Memorial Day Beer Money to Help EOD Scholarship 2Health News:Funeral Financials Asks Americans to Donate their Memorial Day Beer Money to Help EOD Scholarship 3Health News:RADPrimer 3.0 Introduces Comprehensive Radiology Training Curriculum 2
... African swine fever, a devastating pig disease that could ... Organisation said Friday. ,"This is a dramatic ... the Rome-based FAO, noting that the highly contagious viral ... since 1990." ,Armenia, Azerbaidjan and Russia "should ...
... survivors can halve the risk of dying from the disease ... of their weight, suggests a longitudinal study from the ... (UCSD). ,Published in the Journal of Clinical Oncology, ... of a combination of both healthy diet and physical activity ...
... aging in fruit flies with a new technique that shows ... triumph for pests, scientists have found out how to make ... may still have something for humans. As reported online in ... slow down aging holds implications for humans prolonged existence and ...
... diagnosed cancer in men. More than 218,000 men will be ... 27,000 will die . June is Prostate Cancer Awareness Month, ... about the ways men can keep their prostates healthy and ... caused by benign prostatic enlargement affect the vast majority of ...
... department of Health today confirmed the death of a Madison County ... case in 2007 and it seems to be much earlier ... due to the virus. ,Four Mississippians have contracted West ... according to the Health Department and the Centers for Disease Control ...
... gave birth to twins at a hospital in London, where she ... ,The 47-year-old and her husband of ten years, Paul Berges, ... only next month. ,Predicting the early arrival of twins, ... and that she and Berges are really thrilled about it. ...
Cached Medicine News:Health News:Healthy Diet, Exercise can Halve the Risk of Mortality in Breast Cancer Survivors 2Health News:Super Fruit Fly may Harbor Hope for Human Longevity 2Health News:Tips to Maintain a Healthy Prostate 2Health News:First Case of West Nile Virus Death in Madison County 2
... nonsurgical, physician-administered treatment that can temporarily smooth ... brows in people from 18 to 65 ... treatment of its type approved by the ... Cosmetic is a purified protein produced by ...
... is a non-animal stabilized hyaluronic acid-based ... filler to enter the U.S. market. ... moderate to severe facial wrinkles and ... is injected just under the skins ...
... SCULPTRA™ is an injectable ... poly-L-lactic acid, a biocompatible, biodegradable, ... family. SCULPTRA is reconstituted prior ... of Sterile Water for Injection, ...
... is clinically proven to reduce the appearance ... cream-gel formula combines Retinol, the purest form ... Caffeine. It works deep within skin's surface ... bumpy appearance. Fast absorbing, it has a ...
Medicine Products: